AstraZeneca PLC (AZN)

AZN (NYSE:Drugs) EQUITY
$34.43
pos +0.49
+1.40%
Today's Range: 34.18 - 34.38 | AZN Avg Daily Volume: 2,679,300
Last Update: 08/04/15 - 12:13 PM EDT
Volume: 941,498
YTD Performance: -3.55%
Open: $34.21
Previous Close: $33.94
52 Week Range: $31.61 - $38.12
Oustanding Shares: 2,528,000,000
Market Cap: 85,421,120,000
6-Month Chart
TheStreet Ratings Grade for AZN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 3 3 3
Moderate Buy 0 0 0 0
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.33 2.33 2.33 2.33
Latest Dividend: 0.44
Latest Dividend Yield: 4.08%
Dividend Ex-Date: 08/12/15
Price Earnings Ratio: 33.13
Price Earnings Comparisons:
AZN Sector Avg. S&P 500
33.13 66.80 25.65
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% -6.49% 40.80%
GROWTH 12 Mo 3 Yr CAGR
Revenue 1.50 -0.22 -0.08
Net Income -52.00 -0.88 -0.50
EPS -52.10 -0.87 -0.49
Earnings for AZN:
EBITDA 4.63B
Revenue 26.10B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $0.49 $0.52 $2.13 $2.03
Number of Analysts 2 1 5 5
High Estimate $0.51 $0.52 $2.18 $2.11
Low Estimate $0.46 $0.52 $2.10 $1.91
Prior Year $0.52 $0.38 $2.14 $2.13
Growth Rate (Year over Year) -7.14% 38.16% -0.65% -4.66%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
A look at the high-priced and weak among the most expensive sectors.
This small-cap biotech firm could be in the early stages of a big move.
And four other things you need to know now.
It's almost impossible to get too excited about its success.
That this could be such an open secret is beyond me.
New companies are coming up with major drugs.
Two are biotechs and one is in cyber security.
And four other things you need to know now.
Combined Heinz-Kraft heads a long second-quarter list.
This vaccine maker is now closer to several important milestones.

Columnist Conversations

Market is flat as we approach midday which is not bad performance given the continued sell-off in Apple (AAPL)...
We sold out of our Netflix calls entered last week for a nice double...and rolled them up to a higher strike. ...
Just a quick add to my column on LONG. Why would Ctrip even look at this offer which values eLong at $650 mill...
Helene wrote --"If it gets broken and it's still heading up then it tends to act as very minor resistance." Th...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.